多组学技术辅助胶质瘤治疗的研究进展  

Advances in multi⁃omics technologies for assisting therapeutic strategies in glioma

作　　者：孙翌朔 张伟[1] SUN Yi‐shuo;ZHANG Wei(Department of Neurosurgery,Beijing Tiantan Hospital,Capital Medical University,Beijing 100070,China)

机构地区：[1]首都医科大学附属北京天坛医院神经外科,100070

出　　处：《中国现代神经疾病杂志》2025年第2期136-143,共8页Chinese Journal of Contemporary Neurology and Neurosurgery

基　　金：2022年青年北京学者计划(项目编号:055);北京高校卓越青年科学家计划(项目编号:JWZQ20240101026);北京市医院管理中心“登峰”计划专项经费资助(项目编号:DFL20240503)~~。

摘　　要：胶质瘤的高异质性和耐药性使其临床治疗面临巨大挑战。多组学技术的快速发展,极大地促进对胶质瘤分子机制、耐药特征及潜在新药靶点的深入理解。在此基础上,多组学数据用于药物筛选、作用机制解析和临床试验指导,从而加速新型和精准治疗策略在胶质瘤治疗中的转化应用。本文重点介绍近年多组学技术在胶质瘤药物研发中的最新进展,通过揭示胶质瘤的遗传变异、基因表达、蛋白质功能及代谢重编程等特征,辅助胶质瘤分子机制、耐药性和微环境复杂性研究,并为新药靶点的挖掘、精准治疗方案的制定及药物筛选提供重要支持,推动胶质瘤个性化治疗与精准医学的发展。The high heterogeneity and resistance of glioma present significant challenges in clinical treatment.The rapid development of multi‐omics technologies has greatly advanced the understanding of the molecular mechanisms,resistance characteristics,and potential new drug targets in glioma.Building on this,multi‐omics data is now being used for drug screening,mechanism exploration,and clinical trial guidance,thereby accelerating the translation of novel therapies and precision medicine strategies into clinical applications for the treatment of glioma.This review focuses on the latest advancements in the application of multi‐omics technologies in glioma drug research and development,highlighting how insights into genetic mutations,gene expression,protein functions,and metabolic reprogramming can aid in understanding the molecular mechanisms,resistance,and complexity of the tumor microenvironment.Furthermore,it provides critical support for the identification of new drug targets,the development of personalized treatment plans,and drug screening,thus advancing the field of personalized and precision medicine in the treatment of glioma.

关 键 词：神经胶质瘤 多组学技术(非MeSH词) 药物疗法 综述 

分 类 号：R739.41[医药卫生—肿瘤]